Clinical Trial Update: Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery [NA]

View source ↗

Summary

A clinical trial evaluating azacitidine for triple-negative breast cancer across stages I–IV and recurrent disease has been withdrawn (sponsor: University of So…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: University of Southern California | Conditions: Recurrent Breast Cancer, Stage IA Breast Cancer | NA | Status: WITHDRAWN